Rik Bryan qualified in Medicine at the University of Birmingham and subsequently entered surgical training. After completing a PhD in bladder cancer biology he became a Specialist Registrar in Urology.
After 3-years as a Specialist Registrar, Rik left clinical urology to assist with the set-up of the Bladder Cancer Prognosis Programme in the Department of Public Health, Epidemiology and Biostatistics at the University of Birmingham, and was then subsequently appointed as a Senior Research Fellow in the School of Cancer Sciences. Rik is now the Chief Investigator of the Bladder Cancer Prognosis Programme, which incorporates the SELENIB clinical trial.
Rik has an interest in all aspects of bladder cancer, from optical technologies and surgical techniques to biomarker discovery and molecular pathways. His particular interests are narrow band imaging cystoscopy, urinary biomarkers, and cadherin biology, and he has a track record of publication in these specific areas.